The COVID R&D Alliance brings together the world’s most experienced and accomplished leaders in therapeutic drug research and development, and the resources of their organizations to identify, study, and accelerate the most promising candidates across a broad spectrum of therapies and vaccines.
Unconstrained by “how things have been done in the past,” companies with expedited programs already underway are finding synergies and advancing candidates faster than a single company, government, or NGO can alone.
In our race against COVID-19, time is our enemy. Every achievement—no matter how small—brings us a step closer to helping critically ill patients and protecting public health and communities.
The collaboration extends across the drug research and development continuum, including approved medicines, novel therapies, antibodies, and vaccines.
COVID R&D Alliance is focused on finding treatments through shared expertise, data, and evaluation of drug candidates. A win for one, is a win for all.
Pragmatism, speed, and hope propel us, and our combined efforts are already yielding progress.
Through our collaborative efforts, we have analyzed more than 1,900 potential medicines from our members’ pipelines to identify the most promising approaches to advance from lab to clinic. Results from about 40 clinical trials from alliance members are expected to read out near-term.
Over time, COVID R&D Alliance efforts will expand to identify and test early-stage candidates and antivirals. We are united in our goal: identify medicines, medicine combinations, and vaccines to prevent COVID-19’s deadly symptoms or stop them in their tracks. There is no time to wait.
Our members represent more than 20 leading life sciences companies, all working together to identify and accelerate promising therapeutic candidates for COVID-19 and its related symptoms.
Our mission is to stop the deadly symptoms and spread of COVID-19 by collectively identifying and accelerating potential therapies, vaccines, and learnings faster than any organization operating alone could achieve.
We are evaluating a comprehensive spectrum of candidates including: 1) marketed and late-phase development agents, including immunomodulators, 2) novel antibodies, and 3) anti-virals.
Our approach leverages:
We have multiple working groups operating in parallel, with a focus on:
The need to address COVID-19 is urgent and undeniable. Our efforts are complementary to other accelerators, NGOs, and governmental initiatives—and several of our members have engagement with, and candidates involved in, other programs. We are communicating and sharing our efforts across regions, regulators, and other development efforts, which is key to avoid duplication and inefficiencies as the world races to find therapies for COVID-19.
COVID R&D Alliance members are also coordinating with other bodies, including National Institute of Health (NIH), the Bill & Melinda Gates Foundation, U.S. and European trade groups and regulators, among others, to maximize our collective efforts.
Our work is focused on finding treatments through shared expertise, data, and evaluation of drug candidates. A win for one, is a win for all. The world is counting on us.
Many of our members are posting de-identified clinical trial data in a secure master repository to enable greater levels of transparency and sharing to facilitate insights more quickly. With respect to COVID-19 Clinical Trial data, we are working with TransCelerate’s DataCelerate platform to enable our member companies to share data from ongoing and planned COVID-19 studies, as well as findings from past trials. The effort uses de-identified, anonymized pre-clinical and clinical data shared voluntarily by member companies and, in some instances, converted into harmonized data models. The method is compliant for protecting privacy while still helping to power insights.
Once available, COVID R&D Alliance plans to share the aggregate and patient-level data for investigational products, as well as standard of care best practices, via a third-party platform. We will be transparent with our successes and failures, as we all benefit from understanding mechanisms that hold the greatest promise and eliminating those that do not.
BioCentury’s COVID-19 Resource Center will be an additional information sharing resource to disseminate learnings to the greater public health and development community.